US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 17:38:09 Source:sportViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:US overdose deaths dropped in 2023, the first time since 2018
Next:Adams, Reyna, Turner, Ream are US concerns ahead of Copa America
You may also like
- Justin Timberlake set to bring his The Forget Tomorrow World Tour to Australia in 2025
- Arrest warrant issued for man in fatal shooting of off
- 3 dead in east China residential complex fire
- British troops may be tasked with delivering Gaza aid, BBC report says
- Nadal returns to Roland Garros to practice amid doubts over fitness and form
- World benefits from greater China
- China firmly opposes recent US
- Chinese tourist arrivals to Cambodia's Angkor up significantly
- Philippines blames China for loss of giant clams in disputed shoal and urges environmental inquiry